COVID-19 Resources > COVID-19 Web Series FAQs > Vaccine

ACMT COVID-19 Web Series FAQs


The ACMT COVID-19 webinars have focused on vaccines 4 times between July 2020 and January 2021. While the focus shifted from anticipation of a vaccination strategy with phase II and III studies anticipated [July 8, 2020 webinar by Evan Anderson MD of Emory University] and background discussion of the basis for confidence in safety and efficacy testing of developing vaccines [September 16, 2020 webinar by Narayan Nair MD from U.S. FDA and Daniel Shepshelovich MD from Tel Aviv Sourasky Medical Center] to specifics of the varying types of SARS-CoV-2 vaccines in trials [October 28, 2020 webinar by Dr. Evan Anderson] and then back to a strategy and implementation of newly approved vaccine administration prioritization [January 6, 2021 webinar by Satish Pillai, Senior Liaison to Operation Warp Speed], questions from all of these webinars centered on some of the same topics: How do previous vaccine work and safety assessments relate to new vaccines for this RNA virus? What is the best way to use vaccines (in addition to ongoing emphasis on hand hygiene, social distancing and masking when that is not possible, testing and contact notification) to lessen the impact and shorten the pandemic? The following FAQs address some of these persistent questions.

FAQs - Vaccine

Last updated: February 3, 2021